- Investing Ideas
- Swiss Pharmaceuticals & Biotech Large Cap High Growth Potential
Swiss Pharmaceuticals & Biotech Large Cap High Growth Potential
Results
4
Large Cap Companies that analysts expect to have high earnings, revenue or cash flow growth in the next 3 years.
4 companies
Galderma Group
Market Cap: CHF 36.4b
Operates as a dermatology company worldwide.
GALD
CHF 155.05
7D
-2.4%
1Y
97.4%
Sandoz Group
Market Cap: CHF 28.8b
Develops, manufactures, and markets generic and biosimilars worldwide.
SDZ
CHF 66.56
7D
0.7%
1Y
104.6%
Novartis
Market Cap: CHF 225.6b
Researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.
NOVN
CHF 118.22
7D
-2.0%
1Y
30.4%
Lonza Group
Market Cap: CHF 36.7b
Operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally.
LONN
CHF 526.00
7D
1.7%
1Y
-2.4%